Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327720 | PMC |
| http://dx.doi.org/10.3324/haematol.2020.277392 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Highly efficient GPCR immobilization with enhanced fouling resistance, salt tolerance, and chromatographic performance.
Colloids Surf B Biointerfaces
April 2024
Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, College of Life Sciences, Northwest University, Xi'an 710069, China. Electronic address:
Article Synopsis
- The study presents a new method for immobilizing G protein-coupled receptors (GPCRs) using polyethylene glycol (PEG) combined with a self-labeling enzyme-catalyzed reaction to enhance detection reliability.
- It focuses on reducing non-specific interactions at the protein-coating surface, which have been a major issue in previous immobilization strategies, improving the overall performance of biodetection systems.
- The novelty of this research lies in its introduction of PEGylation in GPCR immobilization, showcasing enhanced antifouling properties, salt tolerance, and better chromatographic performance compared to traditional methods.
Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies.
Front Cell Dev Biol
October 2023
Targeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
The glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab has been licensed for treatment in follicular non-Hodgkin lymphoma and B-CLL following clinical trials demonstrating superior outcomes to standard of care treatment. However, ultimately many patients still relapse, highlighting the need to understand the mechanisms behind treatment failure to improve patient care. Resistance to chemotherapy is often caused by the ability of malignant B-cells to migrate to the bone marrow and home into the stromal layer.
View Article and Find Full Text PDFUSP14 promotes the malignant progression and ibrutinib resistance of mantle cell lymphoma by stabilizing XPO1.
Int J Med Sci
April 2023
Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, 310016, PR. China.
Mantle cell lymphoma (MCL) is a heterogeneous disease belonging to non-Hodgkin's lymphoma. In recent years, the morbidity rate of MCL is ascending, and the prognosis remains unfavorable. Ubiquitin-specific proteases14 (USP14) has been evidenced to be engaged in the process of malignant tumors.
View Article and Find Full Text PDFIdentification and Biological Evaluation of a Water-Soluble Fullerene Nanomaterial as BTK Kinase Inhibitor.
Int J Nanomedicine
April 2023
Institute of Chemistry, University of Silesia in Katowice, Katowice, Poland.
Introduction: Thanks to recent advances in synthetic methodology, water-soluble fullerene nanomaterials that interfere with biomolecules, especially DNA/RNA and selected proteins, have been found with tremendous potential for applications in nanomedicine. Herein, we describe the synthesis and evaluation of a water-soluble glycine-derived [60]fullerene hexakisadduct (HDGF) with T symmetry, which is a first-in-class BTK protein inhibitor.
Methods: We synthesized and characterized glycine derived [60]fullerene using NMR, ESI-MS, and ATR-FT-IR.
Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma.
PLoS One
March 2023
Moores Cancer Center, Division of Hematology, Department of Medicine, University of California, San Diego, San Diego, California, United States of America.
Luxeptinib (LUX) is a novel oral kinase inhibitor that inhibits FLT3 and also interferes with signaling from the BCR and cell surface TLRs, as well as activation of the NLRP3 inflammasome. Ongoing clinical trials are testing its activity in patients with lymphoma and AML. This study sought to refine understanding of how LUX modulates the earliest steps downstream of the BCR following its activation by anti-IgM in lymphoma cells in comparison to ibrutinib (IB).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!